Dendritic cells (II): Role and therapeutic implications in cancer

Journal of the Royal College of Surgeons of Edinburgh

Volumn 46, Issue 3, 2001, Pages 159-167

  Satthaporn, S ^a   Eremin, O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cytotoxic cells; Dendritic cells; Tumour associated antigens; Vaccination immuno therapy

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; BONE MARROW; BREAST CANCER; CANCER; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL ISOLATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG PULSE THERAPY; HOST; HUMAN; IMMUNE SYSTEM; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHENOTYPE; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; VACCINATION;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY, ACTIVE; NEOPLASMS; T-LYMPHOCYTES;

EID: 0034955464     PISSN: 00358835     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Dendritic cells
2. Dendritic cell vaccines for cancer immunotherapy
3. Dendritic cells: A link between innate and adaptive immunity
4. Immunohistological skin investigations in patients with the acquired immune deficiency syndrome
5. Follicular dendritic cell function and murine AIDS
6. Langerhans' cells are depleted in chronic graft versus host disease
7. Kaposi's sarcoma in renal transplant recipients: Pathogenetic relation between the reduced density of Langerhans cells and cyclosporin-A therapy
8. Epidermal Langerhans' cells in children with primary T-cell immune deficiencies
9. Human immunodeficiency virus nef gene expression affects generation and function of human T cells, but not dendritic cells
10. The importance of defining the paraneoplastic neurologic disorders
11. Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain
12. Tumour immunology: The glass is half full
13. Cancer vaccines
14. Escape from host-anti-tumor immunity
15. Dendritic cells (I): Biological functions
16. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells
17. Developmental regulation of MHC class II transport in mouse dendritic cells
18. IL-10 inhibits tumor antigen presentation by epidermal antigen- presenting cells
19. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor
20. Interleukin-10 inhibits cytokine synthesis by human monocytes
21. Differential effects of interleukin-10 on the production of interleukin-12 and interleukin-8 by human dendritic cells generated from peripheral blood
22. IL-10 inhibits the primary allogeneic T cell response to human peripheral blood dendritic cells
23. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance
24. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages
25. IL-10 transgenic mice present a defect in T cell development reminiscent of SCID patients
26. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells
27. Tumor rejection after direct co-stimulation of CD8+ TO cells by B7-transfected melanoma cells
28. Specificity and longevity of anti-tumor immune responses induced by B7-transfected tumors
29. + cytolytic T lymphocytes
30. T cell activation determined by T cell receptor number and tunable thresholds
31. Quantitative contribution of CD4 and CD8 to T cell antigen receptor serial triggering
32. T cell responses are governed by avidity and co-stimulatory thresholds
33. Tumor-infiltrating dendritic cells are defective in their antigen- presenting function and inducible B7 expression in rats
34. Mechanism for dendritic cell dysfunction in retroviral infection of mice
35. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors
36. Mouse tumour-associated macrophages do not generate pro coagulation activity in response to different stimuli
37. Depressed monocyte polarisation and clustering of dendritic cells in patients with head and neck cancer: In vitro restoration of this immunosuppression by thymic hormones
38. Tumour-associated macrophages (TAMS): Disordered function, immune suppression and progressive tumour growth
39. + T cell activity
40. Activated macrophages induces structural abnormalities of the T cell receptor-CD3 complex
41. Epidermal cell presentation of tumor-associated antigens for induction of tolerance
42. Role of bone marrow-derived cells in presenting MHC class I-restricted tumour antigen
43. Characterisation of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules
44. Dendritic antigen-presenting cells from the peripheral blood of renal- cell-carcinoma patients
45. Clinical significance of defective dendritic cell differentiation in cancer
46. Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells
47. Dendritic cell differentiation pathways of CD34+ cells from the peripheral blood of head and neck cancer patients
48. Decreased antigen presentation by dendritic cells in patients with breast cancer
49. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas
50. Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: A study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome
51. Immunohistochemical localisation of CD1a-positive putative dendritic cells in human breast tumours
52. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
53. Direct and indirect T cell priming by dendritic cell vaccines
54. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma
55. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
56. Therapy of murine tumors with tumor 7 peptide-pulsed dendritic cells: Dependence on T cells, B7 co-stimulation, and T helper cell 1-associated cytokines
57. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
58. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumour immunity
59. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based anti-tumor vaccines
60. Murine dendritic cells pulsed with whole tumor lysates mediate potent anti-tumor immune responses in vitro and in vivo
61. Induction of antitumor activity by immunisation with fusions of dendritic and carcinoma cells
62. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
63. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
64. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic anti-tumor immunity
65. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
66. Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells
67. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
68. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
69. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
70. Dendritic cells in the T-cell areas of lymphoid organs
71. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T- lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
72. Proliferating dendritic cell progenitors in human blood
73. Dendritic cells as the terminal stage of monocyte differentiation
74. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells
75. Type I IFNs enhance the terminal differentiation of dendritic cells
76. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
77. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro
78. Human dendritic cells. Enrichment and characterisation from peripheral blood
79. Accessory cell requirements for the mixed-leukocyte reaction and polyclonal mitogens, as studied with a new technique for enriching blood dendritic cells
80. Isolation of human blood dendritic cells by discontinuous Nycodenz gradient centrifugation
81. Non-adherent, low-density cells from human peripheral blood contain dendritic cells and monocytes, both with veiled morphology
82. Immunisation with dendritic cells pulsed with xenogeneic prostatic acid phosphatase administered via different routes induces cellular immune responses in prostate cancer patients
83. Dendritic cells injected via different routes induce immunity in cancer patients
84. Dendritic cells in anti-tumor immune responses. II. Dendritic cells growth from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors
85. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines
86. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
87. Genetic immunisation for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells
88. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma
89. Generation of T-cell immunity to a murine melanoma using MART-1- engineered dendritic cells
90. The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting CD4+ T cells in vitro
91. Optimisation of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells
92. IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer
93. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
94. Antigen-specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells
95. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes
96. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
97. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy
98. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
99. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
100. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial
101. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
102. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
103. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma
104. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
105. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
106. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells